Blood-Based Biomarker Market Size, Share & Trends Analysis Report By Type (Screening Biomarker, Diagnosis Biomarker, Others), By Disease (Cancer, Neurological Disorders, Others), By Application (Diagnostics, Drug Discovery, Personalized Medicine), By Region, And By Segment Forecasts, 2025-2034

Global Blood-Based Biomarker Market Size is valued at USD 7.9 Bn in 2024 and is predicted to reach USD 15.9 Bn by the year 2034 at a 7.4% CAGR during the forecast period for 2025-2034.

A blood-based biomarker refers to a measurable and quantifiable characteristic in the blood that indicates a particular physiological or pathological process, or a response to a therapeutic intervention. Biomarkers are valuable tools in medicine and research as they can provide information about normal biological processes, the presence of disease, or the response to treatment.

Blood-based biomarkers can assist in quantifying health and disease by measuring an individual's biochemistry from a simple patient blood sample. Several factors influence the blood-based biomarker market, contributing to its growth and development. These drives are frequently related to technological developments, a better understanding of disease causes, and a demand for personalized and non-invasive diagnostic methods.

However, the COVID-19 pandemic has had a substantial influence on various industries, including the healthcare industry and diagnostic markets, and has had an impact on the blood-based biomarker business. The epidemic shifted research emphasis to better understanding and managing COVID-19. Resources and efforts that were previously devoted to other diseases and biomarker research may have been redirected, potentially affecting timetables for the creation of specific blood-based biomarkers.

Market Segmentation:

The Blood-Based Biomarker Market is segmented based on type, disease, and application. Based on type, the market is segmented as Screening Biomarkers, Diagnosis Biomarkers, and Others. The disease segment includes Cancer, Neurological Disorders, and Others. The application segment is segmented into Diagnostics, Drug Discovery, and Personalized Medicine. 

Based On Type, The Diagnosis Biomarker Segment Is Accounted As A Major Contributor In The Blood-Based Biomarker Market 

The Diagnosis Biomarker category is expected to hold a major share in the global Blood-Based Biomarker Market in 2022. Various factors that contribute to the development, use, and progress of biomarker-based diagnostic technologies drive the blood-based biomarker-based diagnosis market. These factors represent the increasing significance of blood-based biomarkers in personalized medicine, disease identification, and therapy monitoring. Technological advances in genomes, proteomics, and metabolomics enable identifying and validating new blood-based biomarkers. High-throughput sequencing, mass spectrometry, and other omics techniques aid in discovering disease-specific biomarkers.

Cancer Segment Is Witnessing Growth At A Rapid Rate.

The Cancer segment is projected to grow rapidly in the global Blood-Based Biomarker Market. Various factors contribute to the development, use, and progress of biomarker technologies for cancer diagnosis, prognosis, and therapy monitoring, which drive the blood-based biomarker for the cancer market. Ongoing advances in genomes, proteomics, and other omics technologies help identify new blood-based cancer biomarkers. High-throughput sequencing, mass spectrometry, and other modern approaches aid in discovering and confirming biomarkers.

In The Region, The North American Blood Biomarker Market Holds A Significant Revenue Share.

The North American Blood Biomarker Market is expected to register the maximum market share in revenue in the near future. The expanding usage of such markers in personalized medicine and various commercial expansion tactics employed by market players, such as partnerships and collaborations with existing pharmaceutical and biotechnological businesses in this region, can be credited to the region's substantial share. The Asia Pacific region is witnessing an increase in the prevalence of cancer, which is linked to several reasons, such as ageing populations, altered lifestyles, and exposure to environmental variables. This raises the need for blood-based biomarkers to detect and track cancer.

Recent Developments:

• In May 2023, Proteomedix made an official declaration regarding the agreement that has been reached, whereby Labcorp will take sole responsibility for developing and commercialising the Proclarix® Prostate Specific Antigen (PSA) test within the United States. Proclarix was developed to assist in identifying the risk of prostate cancer in men without a cancer suspicion who had an elevated total prostate-specific antigen (PSA) and a digital rectal examination demonstrating an enlarged prostate volume. The procedure utilized the identical blood sample as the PSA test. When applicable, the test provided a non-invasive substitute for a prostate biopsy, a procedure known for its substantial adverse effects. 

Blood-Based Biomarker Market Report Scope